TransCode Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	17.81	5.81	2.77	4.97	20.83
Cash & Short-Term Investments	17.81	5.81	2.77	4.97	20.83
Cash Growth	206.54%	109.97%	-44.30%	-76.14%	2415.16%
Other Receivables	0.95	-	-	0.36	-
Total Trade Receivables	0.95	-	-	0.36	-
Other Current Assets	3.22	1.28	1.69	2.05	1.91
Total Current Assets	21.98	7.09	4.46	7.38	22.73
Net Property, Plant & Equipment	0.37	0.09	0.6	0.21	0.21
Other Intangible Assets	114.3	-	-	-	-
Goodwill	25.74	-	-	-	-
Other Long-Term Assets	-	0.11	0.11	-	-
Total Assets	162.4	7.29	5.17	7.59	22.94
Accounts Payable	3.49	2.71	3.05	4.35	2.5
Current Portion of Leases	-	0.04	0.41	-	-
Unearned Revenue	-	0.03	0.03	-	0.03
Total Current Liabilities	3.49	2.77	3.49	4.35	2.53
Long-Term Leases	-	-	0.04	-	-
Other Long-Term Liabilities	7.02	6.54	-	-	-
Total Long-Term Liabilities	7.02	6.54	0.04	-	-
Total Liabilities	10.52	9.31	3.53	4.35	2.53
Common Stock	0	0	0	0	0
Additional Paid-in Capital	108.2	61.18	48.06	31.11	30.71
Retained Earnings	-97.86	-63.2	-46.42	-27.87	-10.31
Total Common Shareholders' Equity	10.34	-2.02	1.64	3.24	20.4
Minority Interest	141.55	-	-	-	-
Shareholders' Equity	151.88	-2.02	1.64	3.24	20.4
Total Liabilities & Equity	162.4	7.29	5.17	7.59	22.94
Total Debt	0	0.04	0.45	0	0
Net Cash (Debt)	17.81	5.77	2.32	4.97	20.83
Net Cash Growth	208.58%	149.14%	-53.36%	-76.14%	-
Net Cash Per Share	25.83	459.69	11961.09	282999.27	1186235.14
Book Value	10.34	-2.02	1.64	3.24	20.4
Book Value Per Share	14.99	-160.75	8470.28	184589.00	1162220.00
Tangible Book Value	-129.71	-2.02	1.64	3.24	20.4
Tangible Book Value Per Share	-188.06	-160.75	8470.28	184589.00	1162220.00

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q